{"id":"W2576796004","doi":"10.1136/esmoopen-2016-000118","title":"Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy","year":2016,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Samsung; Genentech; Eisai; Amgen; Ariad Pharmaceuticals; Boehringer Ingelheim; Helsinn; Clovis Oncology; Sanofi; Helsinn Therapeutics; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Atezolizumab; Medicine; Ramucirumab; Nivolumab; Oncology; Internal medicine; Chemotherapy; Lung cancer; Immunotherapy; Nintedanib; Cancer; Lung","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008632101,0.000237498,0.001293529,0.001175212,0.0001706927,0.0007602307,0.0003729943,0.00077482,0.002879797],"category_scores_gemma":[0.002614426,0.0001189528,0.001308072,0.0009952845,0.000148542,0.0008941295,0.0003237611,0.0005591393,0.0003782679],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004016472,"about_ca_system_score_gemma":0.0007435254,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000472249,"about_ca_topic_score_gemma":0.001226959,"domain_scores_codex":[0.9995292,0.0001533486,0.0001546271,0.0000410058,0.00009199965,0.00002978406],"domain_scores_gemma":[0.9990371,0.0005505923,0.0002352297,0.00001571511,0.0001274835,0.00003398653],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.00169289,0.0001280603,0.003677734,0.1400477,0.001457669,0.002492956,0.0003478835,0.0002313992,0.002908782,0.001328294,0.01505467,0.830632],"study_design_scores_gemma":[0.001665906,0.003170704,0.0253465,0.1002231,0.008969306,0.01502919,0.0008795434,0.0003646449,0.00342137,0.002242943,0.8386162,0.00007055305],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.002376931,0.9954977,0.00006993,0.0003835822,0.0001849439,0.00002660843,0.00005166336,0.000003009251,0.00140566],"genre_scores_gemma":[0.03492109,0.9619241,0.0005219846,0.001040451,0.0004244126,0.00007699237,0.0001989493,0.000002935122,0.0008891134],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.002879797,"threshold_uncertainty_score":0.009633899,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01509609863842119,"score_gpt":0.3330041230318293,"score_spread":0.3179080243934081,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}